Multiple sclerosis: disease modifying therapy and the human leukocyte antigen
نویسندگان
چکیده
منابع مشابه
Disease Modifying Therapy in Multiple Sclerosis
Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammatory demyelination and axonal degeneration. It is the commonest cause of permanent disability in young adults. Environmental and genetic factors have been suggested in its etiology. Currently available disease modifying drugs are only effective in controlling inflammation but not prevention of neu...
متن کاملHuman leukocyte antigen typing in Iraqi multiple sclerosis patients.
OBJECTIVE To assess the relative frequency of human leukocyte antigen (HLA) class I and class II in Iraqi multiple sclerosis (MS) patients, and to ascertain whether they offer any etiologic or protective role. METHODS We conducted this study in the Baghdad MS Clinic and Teaching Laboratory Institute, Medical City, Baghdad Teaching Hospital, Baghdad, Iraq from March to July 2004. We enrolled 4...
متن کاملMultiple sclerosis disease-modifying therapy prescribing patterns in Ontario.
BACKGROUND Differences in Multiple sclerosis (MS) disease-modifying therapy (DMT) prescribing patterns between different groups of neurologists have not been explored. OBJECTIVE To examine concentrations of prescribing patterns and to assess if MS-specialists use a broader range of DMTs relative to general neurologists. METHODS We conducted a cross-sectional study using administrative claim...
متن کاملMultiple sclerosis and disease-modifying therapies.
Mia T. Minen, MD Steven Karceski, MD Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (DMTs) have been developed. These therapies are designed to decrease the number of MS attacks, and to slow the progression of the disease. They have become a standard part of the current treatment for MS. There are different classes of the currently available DM...
متن کاملMultiple Sclerosis: Overview of Disease-Modifying Agents
Multiple sclerosis (MS) is a chronic autoimmune disease that usually affects young adults, causing progressive physical and cognitive disability. Since the 1990s, its treatment has been based on parenteral medications known collectively as immunomodulators. This drug class is considered safe and usually prevents 30% of MS relapses. Drugs in this class exert almost the same efficacy and require ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arquivos de Neuro-Psiquiatria
سال: 2018
ISSN: 1678-4227,0004-282X
DOI: 10.1590/0004-282x20180103